The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 30% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 53%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (5 analysts) rates it none, with a mean price target of $17.
Orion Group Holdings Inc
ORN · the NYSE · USD · Market cap $518M · 2,076 employees
Orion Group Holdings, Inc.
FAIL · Does not pass the screenAt the last full screen
2025-12-31
Screened 2025-12-31 · the tape above runs as of 23:00 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
What this means: price 12.80 against the desk's fair-value range, base estimate 15.06, over the last year.
- Trend Markdown
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options no verdict drawn today, left as found
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against today's price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its markdown label.
Orion Group Holdings Inc holds its Markdown at $12.80. Consolidating, no directional conviction, held for 4 days.
| Phase | Markdown · caution |
| Quantitative state | Consolidating, no directional conviction, held for 4 days |
| Price at the screen | $12.80 |
| Valuation | 58.18 trailing · 19.51 forward price to earnings |
| Values screen | FAIL · score 70.0 |
| Beta | 1.34 |
Five Screens, Shown in Full
Does not pass. Accounts receivable
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 15.63% | Below 33% | Interest-bearing debt is just 15.6% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 0.00% | Below 33% | Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit. | Pass |
| Receivables | 54.62% | Below 49% | Money owed to the company is 54.6% of assets, above the 49% limit. | Fail |
| Revenue purity | 0.00% | Below 5% | Only 0.0% of revenue comes from non-compliant sources, under the 5% line. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
What the Numbers Say It Is WorthThe Fair Value Range
Fair value range in USD, drawn from the 2025-12-31 screen. The gold marker is the market price at the same screen. A 17.7% margin of safety to the base estimate.
Third-party analyst targets: 6 covering, consensus Strong Buy. The average target sits +33% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & ProjectionsWhere it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2025-12-31 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words| Forward P/E | 19.5xpriced for continued growth |
| Trailing P/E | 58.2xexpensive: the price assumes strong growth ahead |
| EPS, trailing | 0.22 |
| EPS, forward | 0.66 |
| Revenue growth | +14.7%steady growth |
| Profit margin | 1.0%barely profitable |
| Return on equity | 5.4%a modest return on shareholder capital |
| FCF yield | -0.92% |
| Debt to equity | 0.78moderate, manageable leverage |
| Current ratio | 1.41adequate liquidity, worth monitoring |
| Beta | 1.34moves a little more than the market |
| Short interest, float | 0.06% |
| 52-week range | 6.44 - 17.40 |
| Moat | NONE |
| Market cap | $518M |
| Employees | 2,076 |
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeORN trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 11.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 30% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 53%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (5 analysts) rates it none, with a mean price target of $17.
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 30% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 53%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (5 analysts) rates it none, with a mean price target of $17.
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
Screened names in the same industry · explore each on its own page.
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 2026-08-06 | Suzan DelBene | Democrat | buy | 250K–500K |
| 2026-08-06 | Suzan DelBene | Democrat | buy | 250K–500K |
| 2026-08-03 | Don Beyer | Democrat | exchange | 15K–50K |
| 2026-08-03 | Don Beyer | Democrat | exchange | 15K–50K |
| 2026-08-03 | Ro Khanna | Democrat | sell | 1K–15K |
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $15.15 | -11.8% | · | $883 | -11.8% |
| 2 months | $11.51 | +16.2% | · | $1,162 | +16.2% |
| 3 months | $10.51 | +27.2% | · | $1,272 | +27.2% |
| 6 months | $11.69 | +14.4% | · | $1,144 | +14.4% |
| 1 year | $8.75 | +52.8% | · | $1,528 | +52.8% |
| 2 years | $10.25 | +30.4% | · | $1,304 | +30.4% |
| 3 years | $2.62 | +410.3% | · | $5,103 | +410.3% |
| 5 years | $5.82 | +129.7% | · | $2,297 | +129.7% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever ORN does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.